The purpose of this study is to determine whether TVT-Secur (TVT-S) (Hammock method) and TVT-Obturator (TVT-O) suburethral sling procedures have equivalent patient satisfaction and clinical efficacy in the treatment of stress urinary incontinence alone or the stress component in mixed urinary incontinence.

To evaluate the efficacy of TVT-S versus TVT-O suburethral slings in the treatment of stress urinary incontinence or the stress incontinence component of mixed urinary incontinence by the presence or absence or urinary incontinence on cough stress test. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

To describe or assess known side effects or complications,post-operative pain, time of return to daily activities of living, improvement in patient quality of life, change in Q-tip test [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Patient satisfaction will be measured by symptom quality of life questionnaires (pre-operatively, 3 months and one year) and patient pain will be measured by verbal analogue rating scale (post-operative day 1 and day 7). Clinical efficacy will be measured by a cough stress test pre-operatively and post-operatively at 3 months and 1 year. A Q-tip test will also be performed pre-operatively and at 3 months and 1 year post-operatively. Subjects will be followed for a minimum of one year to evaluate recurrence of symptoms and complications, including the rate of mesh erosion, time to normal void in the post-operative period, the rate of sling revision, post-operative pain, voiding dysfunction and de novo urgency.

Demonstrate impact of stress urinary incontinence on quality of life questionnaire

Are able to comprehend and sign a written informed consent

Understand and are willing to comply with the study requirements, including agreeing to be available for the follow-up evaluations

Are psychologically stable and suitable for interventions determined by the investigator

Are ambulatory and able to use a toilet independently

Exclusion Criteria:

Patients:

Who are pregnant or planning to become pregnant during the study or in the future

With a elevated post-void residual (defined as PVR > 100cc)

With a bleeding condition or on anti-coagulant therapy

With immunosuppression (i.e. HIV, lymphoma)

With multiple sclerosis or other progressive neurological disease

With evidence of a local or systemic infection, including urinary tract infection

With evidence of intrinsic sphincter deficiency as defined by a maximal urethral closure pressure of <20 cm H2O

Previous sub-urethral sling

Predominant overactive bladder symptoms

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00676273